Specialty pharmaceuticals: Policy initiatives to improve assessment, pricing, prescription, and use

Health Affairs

Volumn 33, Issue 10, 2014, Pages 1745-1750

  Robinson, James C ^a   Howell, Scott ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CARDINAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG; SPECIALTY DRUG; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL DECISION MAKING; DISEASE MANAGEMENT; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; INSURANCE; MEDICAL FEE; PATIENT SAFETY; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT; COST; ECONOMICS; HEALTH INSURANCE; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES;

COST SHARING; DRUG COSTS; HEALTH POLICY; HUMANS; INSURANCE, HEALTH; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 84907809211     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0498     Document Type: Article

References (31)

1. Spatz I, McGee N. Specialty pharmaceuticals. Health Aff (Millwood). Health Policy Brief. 2013 Nov 25.
2. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the Food and Drug Administration experience. J Natl Cancer Inst. 2011;103(8):636-44.
3. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol. 2009;27(26): 4398-405.
4. Food and Drug Administration. Guidance for industry: format and content of proposed Risk Evaluation and Mitigation Strategies (REMS), REMS assessments, and proposed REMS modifications [Internet]. Silver Spring (MD): FDA; 2009 Sep [cited 2014 Aug 20]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm184128.pdf
5. Johnson PE, Dahlman G, Eng K, Garg R, Gottlieb S, Hoffman JM, et al. NCCN oncology Risk Evaluation and Management Strategies white paper: recommendations for stakeholders. J Natl Compr Canc Netw. 2010;8 Suppl 7:S7-S27.
6. Goldenberg MM. Multiple sclerosis review. P T. 2012;37(3):175-84.
7. Food and Drug Administration. FDA drug safety communication; risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab). Silver Spring (MD): FDA; 2010 Feb 5.
8. Pollack A. FDA panel recommends MS drug despite lethal risk. New York Times. 2006 Mar 9.
9. Tunis SR, Berenson RA, Phurrough SE, Mohr PE. Improving the quality and efficiency of the Medicare program through coverage policy. Washington (DC): Urban Institute; 2011 Aug.
10. Hanson K, Bondurant E. Cancer insurance mandates and exceptions. Denver (CO): National Conference of State Legislatures; 2009 Aug.
11. Private insurers serving the Medicare Part D pharmaceutical program also are required to cover all oncology drugs, regardless of price and availability of therapeutic alternatives. Centers for Medicare and Medicaid Services. Medicare prescription drug benefit manual [Internet]. Baltimore (MD): CMS; 2010 Feb 19. Chapter six, Part D drugs and formulary requirements; [cited 2014 Aug 20]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/Chapter6.pdf
12. Dautel N, Haren M, Bluestein K, Sadiwnyk K. Prior authorization tracking tool for rheumatoid arthritis: trends in the marketplace, second quarter 2011. San Francisco (CA): The Zitter Group; 2011.
13. DeMarino JK, Larsen JK. Equity in cancer care: pathways, protocols, and guidelines. J Natl Compr Canc Netw. 2012;10(Suppl 1):S1-9.
14. Surowiecki J. Biotech's hard bargain. New Yorker. 2014 Apr 28.
15. Cook A, Harrison S. How the Medicaid rebates on prescription drugs affects pricing in the pharmaceutical industry. Washington (DC): Congressional Budget Office; 1996 Jan.
16. The Congressional Budget Office (CBO) compares Federal Supply Schedule (FSS) prices to the average wholesale price (AWP), a nowdiscredited index of actual private prices. The AWP typically is marked up approximately 20 percent above a more realistic price index, referred to in the industry as the wholesale acquisition cost (WAC), and the 47 percent CBO estimate of the FSS discount was adjusted down to 27 percent above the WAC by the authors for this paper. Congressional Budget Office. Prices for brandname drugs under selected federal programs. Washington (DC): CBO; 2005 Jun.
17. Government Accountability Office. Drug pricing: manufacturer discounts in the 340B program offer benefits, but federal oversight needs improvement. Washington (DC): GAO; 2011 Sep.
18. Conti RM, Bach PB. Cost consequences of the 340B drug discount program. JAMA. 2013; 309(19):1995-96.
19. Avalere Health. The 340B drug discount program. Washington (DC): Avalere Health; 2013 Winter.
20. Hall J, Ponaman S. Many not-forprofit hospitals not optimizing 340B pharmacy savings [Internet]. Los Angeles (CA): Hospital Council of Southern California; 2011 Sep 28 [cited 2014 Sep 3]. Available from: http://www.hasc.org/briefs-focus/many-not-profit-hospitals-notoptimizing-340b-pharmacy-savings
21. Robinson JC. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Aff (Millwood). 2006;25(5):1205-17.
22. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN Task Force report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1-14.
23. Cote B. Medicare's competitive acquisition program: stats reveal who's in/who's out and why. Oncology Business Review. 2007 Feb:24-30.
24. Sanchez S. Achieving sustainable hospital-physician alignment in oncology. Washington (DC): Advisory Board, Oncology Roundtable; 2012.
25. Newcomer LN, Gould B, Page RD, Donelan SA, Perkins M. Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract. 2014 Jul 8. [Epub ahead of print].
26. Bosserman LD, Verrilli D, McNatt W. Partnering with a payer to develop a value-based medical home pilot; a West Coast practice's experience. AJMC.com [serial on the Internet]. 2012 Sep 20 [cited 2014 Sep 3]. Available from: http://www.ajmc .com/publications/evidence-basedoncology/ 2012/2012-2-vol18-n4/ Partnering-With-a-Payer-to- Develop-a-Value-Based-Medical- Home-Pilot-A-West-Coast-Practices-Experience/
27. AIM Specialty Health.WellPoint Cancer Care Quality Program: supporting oncology practices and your patients [Internet]. Chicago (IL): AIM; 2014 [cited 2014 Sep 3]. Available from: https://wellpoint.aimoncology.com/pdf/ProgramOverview.pdf
28. Bach PB, Mirkin JN, Luke JJ. Episode-based payment for cancer care: a proposed pilot for Medicare. Health Aff (Millwood). 2011;30(3): 500-9.
29. Claxton G, Rae M, Panchal N, Lundy J, Damico A, Osei-Anto A, et al. Employer health benefits: 2013 annual survey. Menlo Park (CA): Kaiser Family Foundation; 2013.
30. Hoadley J, Summer L, Hargrave E, Cubanski J, Neuman T. Analysis of Medicare prescription drug plans in 2011 and key trends since 2006 [Internet]. Menlo Park (CA): Kaiser Family Foundation; 2011 Sep [cited 2014 Aug 21]. (Medicare Policy Issue Brief). Available from: http://kff .org/medicare/report/medicare-rxdrug- plans-2011-and-key-trends/
31. Robinson JC. Applying value-based insurance design to high-cost health services. Health Aff (Millwood). 2010;29(11):2009-16.